Timothy J Seabrook

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice
    Timothy J Seabrook
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Glia 53:776-82. 2006
  2. ncbi request reprint Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response
    Marcel Maier
    Center for Neurological Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 26:4717-28. 2006
  3. ncbi request reprint Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice
    Timothy J Seabrook
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, United States
    Neurobiol Aging 28:813-23. 2007
  4. ncbi request reprint Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice
    Timothy J Seabrook
    Center for Neurologic Diseases, Brigham and Women s Hospital, and Harvard Medical School, NRB 636F, Boston, MA 02115, USA
    Vaccine 22:4075-83. 2004
  5. pmc Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice
    Marcel Maier
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 28:6333-41. 2008
  6. pmc Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet
    Cynthia A Lemere
    Center for Neurologic Diseases, HIM 622, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02215, USA
    Am J Pathol 165:283-97. 2004
  7. ncbi request reprint Novel Abeta immunogens: is shorter better?
    Cynthia A Lemere
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115 USA
    Curr Alzheimer Res 4:427-36. 2007
  8. ncbi request reprint Developing novel immunogens for an effective, safe Alzheimer's disease vaccine
    Marcel Maier
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurodegener Dis 2:267-72. 2005
  9. ncbi request reprint Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans
    Cynthia A Lemere
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Rejuvenation Res 9:77-84. 2006
  10. ncbi request reprint Species-specific immune response to immunization with human versus rodent A beta peptide
    Timothy J Seabrook
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurobiol Aging 25:1141-51. 2004

Detail Information

Publications13

  1. ncbi request reprint Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice
    Timothy J Seabrook
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Glia 53:776-82. 2006
    ..Therefore, anti-inflammatory therapies to suppress microglial activation or function may reduce cytokine production but enhance Abeta plaque formation early in AD...
  2. ncbi request reprint Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response
    Marcel Maier
    Center for Neurological Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 26:4717-28. 2006
    ..Thus, our novel immunogens show promise for future AD vaccines...
  3. ncbi request reprint Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice
    Timothy J Seabrook
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, United States
    Neurobiol Aging 28:813-23. 2007
    ..Anti-Abeta antibodies bound monomeric, oligomeric, and fibrillar Abeta. Our data suggest that dAbeta1-15 may be an effective and potentially safer immunogen for Alzheimer's disease (AD) vaccination...
  4. ncbi request reprint Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice
    Timothy J Seabrook
    Center for Neurologic Diseases, Brigham and Women s Hospital, and Harvard Medical School, NRB 636F, Boston, MA 02115, USA
    Vaccine 22:4075-83. 2004
    ..These data may help explain some differences observed in Abeta immunization studies in mice of various genetic backgrounds and aid in the design of Abeta vaccines...
  5. pmc Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice
    Marcel Maier
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 28:6333-41. 2008
    ..Our results suggest a beneficial role for complement C3 in plaque clearance and neuronal health as well as in modulation of the microglia phenotype...
  6. pmc Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet
    Cynthia A Lemere
    Center for Neurologic Diseases, HIM 622, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02215, USA
    Am J Pathol 165:283-97. 2004
    ..The findings further support Abeta immunotherapy as a potential prevention and treatment of AD...
  7. ncbi request reprint Novel Abeta immunogens: is shorter better?
    Cynthia A Lemere
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115 USA
    Curr Alzheimer Res 4:427-36. 2007
    ..We remain optimistic about the potential of such a vaccine for prevention and treatment of AD...
  8. ncbi request reprint Developing novel immunogens for an effective, safe Alzheimer's disease vaccine
    Marcel Maier
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurodegener Dis 2:267-72. 2005
    ..These data together with published reports from several other groups suggest that a safe, active A beta vaccine is a tenable goal...
  9. ncbi request reprint Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans
    Cynthia A Lemere
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Rejuvenation Res 9:77-84. 2006
    ..The authors remain optimistic about the potential of such a vaccine for the prevention and treatment of AD...
  10. ncbi request reprint Species-specific immune response to immunization with human versus rodent A beta peptide
    Timothy J Seabrook
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurobiol Aging 25:1141-51. 2004
    ..Therefore, immunizing APP-tg and non-tg mice with rodent A beta resulted in a species-specific humoral response with modest T cell reactivity...
  11. ncbi request reprint Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G)
    Marcel Maier
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Vaccine 23:5149-59. 2005
    ..In conclusion, MPL/TDM, in addition to LT(R192G), is an effective adjuvant when combined with Abeta40/42 and may aid in the design of Abeta immunotherapy...
  12. ncbi request reprint Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice
    Cynthia A Lemere
    Department of Neurology, Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Neurochem Res 28:1017-27. 2003
    ..Studies in AD mouse models and wildtype mice may help elucidate the mechanism for these unwanted side effects and will be useful for testing newer, safer vaccines for future use in human clinical trials...
  13. pmc Osteopetrotic (op/op) mice have reduced microglia, no Abeta deposition, and no changes in dopaminergic neurons
    Yoichi Kondo
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA
    J Neuroinflammation 4:31. 2007
    ..The purpose of these studies was to confirm this and to determine if the lack of CSF-1 affects the development of dopaminergic neurons and the expression of CD200, a known microglial inhibitory protein...